drugset
drugset / Trial / NCT04055389

Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis

NCT04055389 ↗

Phase 1 Withdrawn Jonathan Stine Grifols Therapeutics LLC · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

To prevent portal vein thrombosis (PVT) in patients with cirrhosis at risk for PVT by pharmacologic prophylaxis with intravenous antithrombin (AT-III).

Timeline

Start
2021-01-01
Primary completion
2022-02-22
Completion
2022-02-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Antithrombin III Protein / enzyme biologic — Intravenous

Indications

cirrhosis of liver portal vein thrombosis